Spots Global Cancer Trial Database for Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Official Title: Phase II, Multi-center, and Pharmacokinetic Study of Efficacy, Safety and Pharmacokinetic of Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Study ID: NCT02544789
Conditions
Interventions
Study Description
Brief Summary: Outcomes for children with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) are dismal. Therefore, the investigators performed this multicenter, phase II study to evaluate the efficacy and , safety and pharmacokinetic of clofarabine in Chinese pediatric patients with R/R ALL
Detailed Description:
Keywords
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Pediatrics, Peking University People's Hospital, Beijing, , China
Department of Phase 1 Clinical Trial, Peking University People's Hospital, Beijing, , China
Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, , China
The First Affiliated Hospital, Zhejiang University, Hangzhou, , China
The First Hospital of China Medical University, Shenyang, , China
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, , China
Contact Details
Name: Jin Lu, MD
Affiliation: Department of Pediatrics, Peking University People's Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
